American Journal of Laboratory Medicine

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

The Magnitude of Dyslipidemia & Associated Factors Among Patients with Type 2 DM Who Are in Follow-up in Adult Endocrine Clinic at SPHMMC, Addis Ababa, Ethiopia

Diabetes has been a rising health burden universally. It is defined as a group of metabolic disorders that result in high serum glucose levels which can be caused by a deficiency of insulin or a defect in its action. Cardiovascular complication is the main cause of death in the diabetic population. Of which, dyslipidemia is the principal factor associated with cardiovascular disease in the T2DM population. However, early detection and treatment of dyslipidemia in T2DM patients can prevent the progression of dyslipidemia & minimize the risk of CVS disease-related morbidity and death significantly. And for there is a paucity of data on the magnitude of dyslipidemia & associated factors among T2DM patients in Ethiopia, we conducted an institution-based cross-sectional analytic study at SPHMMC endocrinology clinic from January 1 to February 28 2022 G.C. The data for the study is collected by a structured checklist and it is entered, cleaned & analyzed using SPSS version 26.0. Descriptive analyses like frequency distribution, proportion and dispersion were calculated. And the finding is presented using frequency tables, graphs, and charts. Both univariate and multivariate analyses were done. The OR with 95% CI was used to show the strength of the association and a P value of <0.05 was considered statistically significant. In the study, a total of 270 type 2 DM patients were enrolled and all of them were included in the analysis. The magnitude of dyslipidemia revealed from the study was 93.7%. Out of those who have dyslipidemia, 13.7%, 64.8%, 70% and 34.8% of the participants had high TC, low HDL, high LDL and high triglyceride levels, respectively. In multiple regression analysis, only sex showed statistical significance at p-value < 0.05. The odds of having dyslipidemia was 7-fold increased (AOR=95% CI (1.251-43.421)) in type 2 DM patients. As a conclusion, the magnitude of dyslipidemia was found to be 93.7% of the total participants which is higher than most of the studies which were done inside and outside Ethiopia. And being female was associated with a risk of developing dyslipidemia. Thus, health professionals should screen and monitor dyslipidemia in all type 2 DM patients especially females.

T2DM, Dyslipidemia, FBG, HbA1C, Endocrinology Clinic, SPHMMC

APA Style

Tsion Habtamu Ababiya, Robel Habtamu Ababiya, Yohannes Gizachew Achamyeleh, Peniel Yigezu Sedi, Rediet Ajebu Nurfeta, et al. (2023). The Magnitude of Dyslipidemia & Associated Factors Among Patients with Type 2 DM Who Are in Follow-up in Adult Endocrine Clinic at SPHMMC, Addis Ababa, Ethiopia. American Journal of Laboratory Medicine, 8(2), 13-20. https://doi.org/10.11648/j.ajlm.20230802.11

ACS Style

Tsion Habtamu Ababiya; Robel Habtamu Ababiya; Yohannes Gizachew Achamyeleh; Peniel Yigezu Sedi; Rediet Ajebu Nurfeta, et al. The Magnitude of Dyslipidemia & Associated Factors Among Patients with Type 2 DM Who Are in Follow-up in Adult Endocrine Clinic at SPHMMC, Addis Ababa, Ethiopia. Am. J. Lab. Med. 2023, 8(2), 13-20. doi: 10.11648/j.ajlm.20230802.11

AMA Style

Tsion Habtamu Ababiya, Robel Habtamu Ababiya, Yohannes Gizachew Achamyeleh, Peniel Yigezu Sedi, Rediet Ajebu Nurfeta, et al. The Magnitude of Dyslipidemia & Associated Factors Among Patients with Type 2 DM Who Are in Follow-up in Adult Endocrine Clinic at SPHMMC, Addis Ababa, Ethiopia. Am J Lab Med. 2023;8(2):13-20. doi: 10.11648/j.ajlm.20230802.11

Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Bekele S, Yohannes T, Eshete A, Mohammed. Dyslipidemia and associated factors among diabetic patients attending durame general hospital in southern nations, nationalities, and people’s region. Diabetes, Metab Syndr Obes Targets Ther. 2017 Jun 22; 10: 265–71.
2. Haile K, Timerga A. Dyslipidemia and its associated risk factors among adult type-2 diabetic patients at jimma university medical center, Jimma, Southwest Ethiopia. Diabetes, Metab Syndr Obes Targets Ther. 2020; 13: 4589–97.
3. Larry Jameson J. HARRISON’S Endocrinology Second Edition. 2010 May 18.
4. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based -studies with 4.4 million participants. Lancet (London, England). 2016 Apr 9; 387 (10027): 1513–30.
5. Animaw W, Seyoum Y. Increasing prevalence of diabetes mellitus in a developing country and its related factors. PLoS One. 2017 Nov 1; 12 (11).
6. Cho N, Kirigia J, Ogurstova K, Reja A. IDF Diabetes Atlas (Internet) [Internet]. 2017. 1–150 p. Available from: www.diabetesatlas.org
7. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Vol. 14, Nature Reviews Endocrinology. Nature Publishing Group; 2018. p. 88–98.
8. Chaudhury D, Aggarwal A. Diabetic dyslipidemia: Current concepts in pathophysiology and management. Vol. 12, Journal of Clinical and Diagnostic Research. Journal of Clinical and Diagnostic Research; 2018. p. OE06–9.
9. Díaz Vera AS, Abellán Alemán J, Segura Fragoso A, Martínez de Esteban JP, Lameiro Couso FJ, Golac Rabanal M del S, et al. The prevalence and risk factors associated with dyslipidemia in type 2 diabetic patients in the autonomous Region of Cantabria. Endocrinol Diabetes y Nutr (English ed). 2020 Feb; 67 (2): 102–12.
10. Zachary T. ADA annual metting. In. 1998.
11. Gebreegziabiher G, Belachew T, Mehari K, Tamiru D. Prevalence of dyslipidemia and associated risk factors among adult residents of Mekelle City, Northern Ethiopia. PLoS One. 2021 Feb 1; 16 (2 February).
12. World Health Report 2002-Reducing Risks, Promoting Healthy Life Methods Summaries for Risk Factors assessed in Chapter 4.
13. BeLue R, Okoror TA, Iwelunmor J, Taylor KD, Degboe AN, Agyemang C, et al. An overview of cardiovascular risk factor burden in sub-Saharan African countries: A socio-cultural perspective. Vol. 5, Globalization and Health. 2009.
14. Cardiovascular disease and risk management: Standards of medical care in diabetesd 2021. Diabetes Care. 2021 Jan 1; 44: S125–50.
15. Daya R, Bayat Z, Raal FJ. Prevalence and pattern of dyslipidaemia in type 2 diabetes mellitus patients at a tertiary care hospital. J Endocrinol Metab Diabetes South Africa. 2017; 22 (3): 31–5.
16. Kiplagat SV, Lydia K, Jemimah K, Drusilla M. Prevalence of Dyslipidemia and The Associated Factors Among Type 2 Diabetes Patients in Turbo Sub-County kenya. J Endocrinol Diabetes. 2017 Dec 21; 4 (5): 1–9.
17. Ciccacci F, Majid N, Petrolati S, Agy M, Massango C, Orlando S, et al. Hypercholesterolemia and related risk factors in a cohort of patients with diabetes and hypertension in maputo, mozambique. Pan Afr Med J. 2021; 38: 1–8.
18. Pitso L, Mofokeng TRP, Nel R. Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa. BMC Endocr Disord. 2021 Dec 1; 21 (1).
19. Narindrarangkura P, Bosl W, Rangsin R, Hatthachote P. Prevalence of dyslipidemia associated with complications in diabetic patients: A nationwide study in Thailand. Lipids Health Dis. 2019 Apr 6; 18 (1).
20. Shahwan MJ, Jairoun AA, Farajallah A, Shanabli S. Prevalence of dyslipidemia and factors affecting lipid profile in patients with type 2 diabetes. Diabetes Metab Syndr Clin Res Rev. 2019 Jul 1; 13 (4): 2387–92.